Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement‐dependent anti‐tumor activity of trastuzumab and pertuzumab

The therapeutic potential of anticancer antibodies is limited by the resistance of tumor cells to complement‐mediated attack, primarily through the over‐expression of membrane complement regulatory proteins (mCRPs: CD46, CD55 and CD59). Trastuzumab, an anti‐ HER2 monoclonal antibody, approved for th...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Mol Oncol
Päätekijät: Mamidi, Srinivas, Cinci, Marc, Hasmann, Max, Fehring, Volker, Kirschfink, Michael
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2013
Aiheet:
Papers
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528480/
https://ncbi.nlm.nih.gov/pubmed/23474221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2013.02.011
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia